A doctor giving recommendations to patient.

Patient is being happy and looking upwards

A doctor is talking with a patient, and both are laughing

smiling young black female doctor psychologist consulting european woman modern clinic interior

Transform brain health through the integration of precision medicine into psychiatry and neurology.

A simple blood test designed to identify the most effective medication for each patient, tailored to their unique biological and clinical profile.

AI-measured Drug Response

Unparallelled Accuracy

Science-Driven Breakthroughs

Precision Medicine. Realized

Get Started

Clinical Studies

Prospective

Observational

Specimen Collection

Therapeutic biomarkers of depression

PI

Karin Borgmann-Winter, MD
Chang-Gyu Hahn MD, PhD (Department of Psychiatry and Human Behavior)

‍DESCRIPTION

The purpose of this study is to identify biomarkers that are associated with treatment responsiveness/resistance to anti-depressants. To that end, we aim to obtain neuronal cells derived from individuals who have well characterized history of responsiveness to treatment. The primary objectives of this study are to identify biomarkers associated with treatment responsiveness and treatment resistance in patients with major depressive disorder (MDD). In doing so, we hope to uncover biomarkers that may help predict appropriate therapy for patients with MDD.

‍

PARTICIPANTS

60 subjects with MDD, 20 antidepressant treatment responsive, 20 antidepressant non-responders, and 20 antidepressant differential responders, enrolled in the study.

learn more

Show less

Prospective

Observational

Specimen Collection

Induction of microglia-like cells from human monocytes as a tool to study schizophrenia disorder

PI

Prof. Alon Shamir, MD, Head, Psychobiology Research Lab - Mazor Mental Health Medical Center
and Muhammad Zoabi, MD

‍DESCRIPTION

This study aims to explore the morphological, molecular, and functional differences between microglia-like cells and neurons derived from schizophrenic patients and healthy individuals. It also seeks to evaluate the impact of antipsychotic treatment on the secretion of pro-inflammatory markers and neuronal activation in these cells.

‍

PARTICIPANTS

The study involves 120 individuals with schizophrenia and 60 healthy control subjects. The 120 individuals with schizophrenia are divided into two groups: those who are experiencing their first episode of schizophrenia or their first hospitalization for acute schizophrenia, and those who are in the non-acute phase of schizophrenia and are receiving antipsychotic treatment.

learn more

Show less

Be Part of Our Early Access Program

We’re excited to invite forward-thinking professionals and organizations to join NeuroKaire's Early Access Program. As a participant, you’ll be among the first to access personalized, evidence-driven insights designed to optimize treatment for every individual patient.

Enrollment is limited—don’t miss this opportunity to pioneer precision care solutions in mental health and neurology.

Get Started

Clinical Studies

Therapeutic biomarkers of depression

PI

‍DESCRIPTION

PARTICIPANTS

Induction of microglia-like cells from human monocytes as a tool to study schizophrenia disorder

PI

‍DESCRIPTION

PARTICIPANTS

Be Part of Our Early Access Program

Contact Us